Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment

Nephrology

Volumn 3, Issue 1, 1997, Pages 117-121

  Lee, G S L ^a   Choong, H L ^a   Chiang, G S C ^a   Woo, K T ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

anticoagulant; antiplatelet; renal function

Indexed keywords

CREATININE; DIPYRIDAMOLE; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030977702     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1997.tb00201.x     Document Type: Conference Paper

References (48)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephroparhy. Q. J. Med. 1987; 245: 709-27.
2. Woo KT, Chiang GSC, Edmondson RPS et al. Glomerulonephritis in Singapore: An overview. Ann. Acad. Med. Singapore 1986; 15: 20-30.
3. Glassock R, Cohen A, Adler S. Primary glomerular disease. In: Brenner B (ed.) The Kidney. 5th edn. WB Saunders, Philadephia, 1995; 1414-21.
4. Cameron JS. The long-term outcome of glomerular disease. In: R Schrier CG (ed.) Disease of the Kidney. Little, Brown Co., Boston, 1993; 1916-16.
5. Clarkson A, Woodroffe A, Bonnister K et al. Therapy in IgA nephropathy. Contrib. Nephrol. 1993; 104: 189-97.
6. Galla J. Perspectives in clinical nephrology. Kidney Int. 1995; 7: 377-87.
7. Murakami K, Yoshioka K, Akano N et al. Combined therapy in children and adolescents with IgA nephropathy. Nippon Jinzo Gakkai Shi 1994; 36: 38-43.
8. Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin. Nephrol. 1990; 34: 103-7.
9. Woo KT, Chiang GS, Yap HK, Lim CH. Controlled therapeutic trial of IgA nephritis with follow-up renal biopsies. Ann. Acad. Med. Singapore 1988; 17: 226-31.
10. Hotta O, Taguma Y, Kurosawa K et al. Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study. Nippon Jinzo Gakkai Shi 1993; 35: 967-73.
11. Shearman JD, Yin ZG, Aarons I et al. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome ot patients with membranous nephropathy. Clin. Nephrol. 1988; 30: 320-9.
12. Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin. Nephrol. 1992; 37: 229-34.
13. Cattran DC, Cardella CJ, Roscoe JM et al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int. 1985; 27: 436-41.
14. Futrakul P, Poshyachinda M, Mitrakul C. Hypercoagulopathy in the nephrotic syndrome: Use of anticoagulation. In: Zurukzoglu, Papadimitriou, Pyrpasopoulous, Soin (eds) Proc. 8th Int. Cong. Nephrol. Karger, Basel, 1981; 297-304.
15. Cameron JS. Platelets in glomerular disease. Ann. Rev. Med. 1984; 175-80.
16. Duffy JL, Clinque T, Grisham E. Intraglomerular fibrin, platelet aggregation and subendothelial deposits in lipoid nephrosis. J. Clin. Invest. 1970; 49: 251-8.
17. Lee GSL, Lau YK, Woo KT. Platelet Factor 4 in IgA nephritis. Clin. Nephrol. 1991; 35: 44.
18. Woo KT, Tan YO, Yap HK, Lau YK, Lim CH. Beta-thromboglobulin in mesangial IgA nephritis. Throm. Res. 1981; 24: 259-62.
19. Woo KT, Lee EJC, Lau YK, Lim CH. Antithrombin III in mesangial IgA nephritis. Thrombosis Research 1985; 40: 483-7.
20. Tan CC, Lee GSL, Lee EJC, Woo KT. Plasma activity of contact coagulation factors in patients with IgA nephritis. Ann. Acad. Med. Singpaore 1996; 25: 218-21.
21. Shigematsu H, Kobayashi Y, Tateno S, Hiki Y, Kuwao Y. Ultrastructural glomerular loop abnormalities in IgA nephritis. Nephron 1982; 30: 1-7.
22. Woo KT, Edmondson RP, Yap HK et al. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin. Nephrol. 1987; 27: 56-64.
23. Schein PS, Winokur SH. Immunosuppressive and cytotoxic chemotherapy: Long term complications. Ann. Int. Med. 1975; 82: 84-95.
24. Fairley KF, Barrie JU, Johnson W. Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet 1972; 1: 568-9.
25. de Gruchy GC. Anticoagulant drugs. In: Gruchy D (ed.) Clinical Haematology in Medical Practice. 3rd edn. Blackwell Science, Oxford, 1979; 696-700.
26. Francis CW, Marder VJ, Evarts CM, Yaukoolbode S. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983; 249: 374-8.
27. Wessler S, Gitel SN. Warfarin: From bedside to bench. N. Engl. J. Med. 1984; 311: 645-52.
28. Woo KT, Lee GSL. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin. Clin. Nephrol. 1991; 35: 184.
29. Nagy J, Milteny M, Dobos M, Burger T. Tubular proteinuria in IgA glomerulonephritis. Clin. Nephrol. 1987; 27: 76-8.
30. Woo KT, Lau YK, Lee GSL, Wei SS, Lim CH. Pattern of proteinuria in IgA nephritis by SDS-PAGE: Clinical significance. Clin. Nephrol. 1991; 36: 6-11.
31. de Jong PE, van de Meer J, van de Hem GK, de Zeeuw D. Is the antiproteinuric effect of dipyridamole hemodynamically mediated? Nephron 1988; 50: 292-4.
32. Arend LJ, Thompson CI, Spielman WS. Dipyridamole decreases glomerular filtration in the sodium-depleted dog. Evidence for mediation by intrarenal adenosine. Circulation. Res. 1985; 56: 242-51.
33. Ischikawa H, Honjo A, Hayashi M et al. Effects of dipyridamole on proteinuria in chronic glomerulonephritis and nephrotic syndrome. Arznei mittelforschung/Drug Res. 1982; 32: 301-9.
34. Cattell J, Mehotra A. Focal mesangial proliferative glomerulonephritis in the rat caused by Habu venim: The effect of antiplatelet agents. Br. J. Exp. Pathol. 1980; 61: 310-14.
35. Lee GSL, Woo KT, Tan HB, Lim CH. Effect of dipyridamole on collagen synthesis in cultured rat mesangial cells. 13th International Congress in Nephrology, Tokyo, 1995; 291.
36. Lee GSL, Woo KT, Tan HB, Lim CH. Effects of dipyridamole on proliferation of cultured rat mesangial cells. 6th International Symposium on IgA Nephropathy. Adelaide, 1994.
37. Tsai T, Lin R, Chen YM et al. Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 1995; 70: 91-9.
38. Oliveria A, Lopez-Novoa J. Effect of adenosine and adenosine analogues on cyclic AMP accumulation in cultured mesangial cells and isolated glomeruli of the rat. Br. J. Pharmacol. 1992; 107: 341-6.
39. Davis M. The mesangial cell: A tissue culture view. Kidney Int. 1994; 45: 320-7.
40. Takehara K, Igarashi A, Ishibashi Y. Dipyridamole specifically decreases platelet-derived growth factor release from platelets. Pharmacology 1990; 40: 150-6.
41. Thornes D. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants. Cancer 1975; 35: 91-7.
42. Thornes RD, Edlow DW, Wood S Jr. Inhibition of the locomotion of cancer cells in vivo by anticoagulation therapy. Effects of sodium warfarin on V2 cancer cells, granulocytes, lymphocytes and macrophages in rabbits. Johns Hopkins Med. J. 1968; 123: 305-16.
43. Berkada J. Preliminary report: Warfarin for the treatment of herpes simplex. J. Irish Coll. Phy. Surg. 1993; 22: 56.
44. Camara S, Cruz JP, Frutos MA et al. Effects of dipyridamole on the short term evolution of glomerulonephritis. Nephron 1991; 58: 13-16.
45. Kan K, Wada T, Kitamoto K et al. Dipyridamole tor protein suppression. JAMA 1974; 229: 557-8.
46. Tojo S, Narita M, Koyama A, Sano M, Suzuki H. Dipyridamole therapy in the nephrotic syndrome. Contrib. Nephrol. 1978; 9: 111-27.
47. Ueda N, Kawaguchi S, Niinomi Y et al. Effect of dipyridamole treatment on proteinuria in paediatric renal disease. Nephron 1986; 44: 174-9.
48. Sakai H, Abe K, Kobayashi Y et al. Clinical guidelines of IgA nephroparhy. Nippon Jinzo Gakkai Shi 1995; 37: 417-21.